{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T08:04:13Z","timestamp":1779696253806,"version":"3.53.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Shenzhen Nanshan District Health Science and Technology Project","award":["NS2023079"],"award-info":[{"award-number":["NS2023079"]}]},{"DOI":"10.13039\/501100004763","name":"Natural Science Foundation of Inner Mongolia Autonomous Region","doi-asserted-by":"crossref","award":["2024LHMS08072"],"award-info":[{"award-number":["2024LHMS08072"]}],"id":[{"id":"10.13039\/501100004763","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82400185"],"award-info":[{"award-number":["82400185"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Fundamental\u00a0Research\u00a0Funds\u00a0for\u00a0the\u00a0Provincial\u00a0Universities of Heilongjiang","award":["2023-KYYWF-0152"],"award-info":[{"award-number":["2023-KYYWF-0152"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although Arsenic trioxide (ATO) has revolutionized acute promyelocytic leukaemia (APL) from a uniformly fatal disease to one of the most curable leukemias, leukocytosis is a common life-threatening side effect and is associated with inferior results. This study aimed to describe leukocyte proliferation kinetics and explore predictors of leukocytosis among APL patients in order to guide individualized application of ATO.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In this retrospective study of 100 patients, the incidence of leukocytosis in the single drug ATO group was 74.5%, while that in the ATO- chemotherapy group was 93.9% (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.018). The dynamic changes in leukocytosis showed a higher WBC count in the ATO-chemotherapy group. The median time to leukocytosis was the 9th day (IQR, 6.00\u201314.00). The duration of leukocytosis was shorter in the ATO single agent group. The uni-variate analysis and multi-variable analysis showed that the same independent prognostic factor was\n                      <jats:italic>the time to double WBC<\/jats:italic>\n                      for leukocytosis for all patients (OR 11.459, 95% CI, 2.121\u201361.897) and ATO single agent patients (OR 16.603, 95% CI, 1.635-168.635). The area under the ROC curve was 0.835 (95% CI, 0.700-0.971) for all APL patients and 0.822 (95% CI, 0.675\u20130.969) for\n                      <jats:italic>single ATO-induced leukocytosis<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      The kinetics of leukocytosis induced by single-agent ATO and ATO-chemotherapy were different.\n                      <jats:italic>The time to double WBC\u22647th day<\/jats:italic>\n                      was identified as an independent poor prognostic factor for single ATO-induced leukocytosis in APL patients.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12672-026-05155-1","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T08:23:42Z","timestamp":1778315022000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictors and kinetics of ATO-induced leukocytosis in acute promyelocytic leukemia patients: a retrospective study"],"prefix":"10.1007","volume":"17","author":[{"given":"Hong","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueli","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqi","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9339-260X","authenticated-orcid":false,"given":"Meijuan","family":"Sui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"issue":"5","key":"5155_CR1","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1111\/bjh.19759","volume":"205","author":"L Cicconi","year":"2024","unstructured":"Cicconi L, Bisegna M, Gurnari C, Fanciullo D, et al. Leucocytosis during induction therapy with all-trans-retinoic acid and arsenic trioxide in acute promyelocytic leukaemia predicts differentiation syndrome and treatment-related complications. Br J Haematol. 2024;205(5):1727\u201333. https:\/\/doi.org\/10.1111\/bjh.19759.","journal-title":"Br J Haematol"},{"issue":"12","key":"5155_CR2","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1007\/s00277-022-04954-0","volume":"101","author":"M Yanada","year":"2022","unstructured":"Yanada M. Treatment for relapsed acute promyelocytic leukemia. Ann Hematol. 2022;101(12):2575\u201382. https:\/\/doi.org\/10.1007\/s00277-022-04954-0.","journal-title":"Ann Hematol"},{"issue":"5","key":"5155_CR3","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/leu.2015.12","volume":"29","author":"E Lengfelder","year":"2015","unstructured":"Lengfelder E, Lo-Coco F, Ades L, et al. Arsenic Trioxide-Based Therapy of Relapsed Acute Promyelocytic Leukemia: Registry Results from the European LeukemiaNet. Leukemia. 2015;29(5):1084\u201391. https:\/\/doi.org\/10.1038\/leu.2015.12.","journal-title":"Leukemia"},{"issue":"14","key":"5155_CR4","doi-asserted-by":"publisher","first-page":"3637","DOI":"10.3390\/cancers15143637","volume":"15","author":"S Kayser","year":"2023","unstructured":"Kayser S, Conneely SE. Management of Acute Promyelocytic Leukemia at Extremes of Age. Cancers (Basel). 2023;15(14):3637. https:\/\/doi.org\/10.3390\/cancers15143637.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"5155_CR5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1053\/shem.2001.20863","volume":"38","author":"Z Chen","year":"2001","unstructured":"Chen Z, Chen GQ, Shen ZX, et al. Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies. Semin Hematol. 2001;38(1):26\u201336. https:\/\/doi.org\/10.1053\/shem.2001.20863.","journal-title":"Semin Hematol"},{"issue":"2","key":"5155_CR6","first-page":"111","volume":"21","author":"J Zhou","year":"2006","unstructured":"Zhou J, Meng R, Sui X, et al. Effects of arsenic trioxide administration styles on leukocytosis. Chin Med Sci J. 2006;21(2):111\u20134.","journal-title":"Chin Med Sci J"},{"key":"5155_CR7","doi-asserted-by":"publisher","first-page":"204062072412996","DOI":"10.1177\/20406207241299699","volume":"15","author":"K Shen","year":"2024","unstructured":"Shen K, Huang J, Chenlu, et al. Standard dose anthracycline plus all-trans retinoic acid and arsenic trioxide as induction chemotherapy significantly reduces early death and relapse for high-risk acute promyelocytic leukemia: a single-center real-world analysis. Ther Adv Hematol. 2024;15:20406207241299699. https:\/\/doi.org\/10.1177\/20406207241299699.","journal-title":"Ther Adv Hematol"},{"issue":"12","key":"5155_CR8","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1515\/cclm-2018-0507","volume":"56","author":"M Avgeris","year":"2018","unstructured":"Avgeris M, Stamati L, Kontos CK, et al. BCL2L12 improves risk stratification and prediction of BFM-chemotherapy response in childhood acute lymphoblastic leukemia. Clin Chem Lab Med. 2018;56(12):2104\u201318. https:\/\/doi.org\/10.1515\/cclm-2018-0507.","journal-title":"Clin Chem Lab Med"},{"issue":"1","key":"5155_CR9","doi-asserted-by":"publisher","first-page":"11935","DOI":"10.1038\/s41598-019-47937-4","volume":"9","author":"J Yoon","year":"2019","unstructured":"Yoon J, Kim H, Min GJ, et al. Progressive hyperleukocytosis is a relevant predictive marker for differentiation syndrome, early death, and subsequent relapse in acute promyelocytic leukemia. Sci Rep. 2019;9(1):11935. https:\/\/doi.org\/10.1038\/s41598-019-47937-4.","journal-title":"Sci Rep"},{"issue":"12","key":"5155_CR10","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1007\/s00277-020-04245-6","volume":"99","author":"H Minamiguchi","year":"2020","unstructured":"Minamiguchi H, Fujita H, Atsuta Y, et al. Predictors of early death, serious hemorrhage, and differentiation syndrome in Japanese patients with acute promyelocytic leukemia. Ann Hematol. 2020;99(12):2787\u2013800. https:\/\/doi.org\/10.1007\/s00277-020-04245-6.","journal-title":"Ann Hematol"},{"issue":"7","key":"5155_CR11","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.leukres.2013.04.011","volume":"37","author":"H Leblebjian","year":"2013","unstructured":"Leblebjian H, DeAngelo DJ, Skirvin JA, et al. Predictive factors for all-trans retinoic acid-related differentiation syndrome in patients with acute promyelocytic leukemia. Leuk Res. 2013;37(7):747\u201351. https:\/\/doi.org\/10.1016\/j.leukres.2013.04.011.","journal-title":"Leuk Res"},{"issue":"10","key":"5155_CR12","doi-asserted-by":"publisher","first-page":"3947","DOI":"10.1007\/s00277-024-05776-y","volume":"103","author":"Y Gao","year":"2024","unstructured":"Gao Y, Xi Y, Chen W, Meng Y, Su Y. Early predictor for differentiation syndrome in newly diagnosed acute promyelocytic leukaemia patients treated with single-agent arsenic trioxide. Ann Hematol. 2024;103(10):3947\u201354. https:\/\/doi.org\/10.1007\/s00277-024-05776-y.","journal-title":"Ann Hematol"},{"issue":"1","key":"5155_CR13","doi-asserted-by":"publisher","first-page":"2191462","DOI":"10.1080\/16078454.2023.2191462","volume":"28","author":"S Kungwankiattichai","year":"2023","unstructured":"Kungwankiattichai S, Owattanapanich W, Rattanathammethee T, et al. Does leukocytosis remain a predictive factor for survival outcomes in patients with acute promyelocytic leukemia receiving ATRA plus a chemotherapy-based regimen: A prospective multicenter analysis from TALWG. Hematology. 2023;28(1):2191462. https:\/\/doi.org\/10.1080\/16078454.2023.2191462.","journal-title":"Hematology"},{"issue":"2","key":"5155_CR14","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1182\/blood.2024026186","volume":"145","author":"MT Voso","year":"2025","unstructured":"Voso MT, Guarnera L, Lehmann S, et al. Acute promyelocytic leukemia: long-term outcomes from the HARMONY project. Blood. 2025;145(2):234\u201343. https:\/\/doi.org\/10.1182\/blood.2024026186.","journal-title":"Blood"},{"issue":"29","key":"5155_CR15","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1200\/JCO-25-00535","volume":"43","author":"U Platzbecker","year":"2025","unstructured":"Platzbecker U, Ad\u00e8s L, Montesinos P, et al. Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial. J Clin Oncol. 2025;43(29):3160\u20139. https:\/\/doi.org\/10.1200\/JCO-25-00535.","journal-title":"J Clin Oncol"},{"issue":"1","key":"5155_CR16","doi-asserted-by":"publisher","first-page":"2231738","DOI":"10.1080\/16078454.2023.2231738","volume":"28","author":"M Sui","year":"2023","unstructured":"Sui M, Wei H, Shen X, et al. Sulfhydryl compound levels are associated with ATO-induced side effects in acute promyelocytic leukemia patients. Hematology. 2023;28(1):2231738. https:\/\/doi.org\/10.1080\/16078454.2023.2231738.","journal-title":"Hematology"},{"key":"5155_CR17","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.leukres.2017.09.006","volume":"61","author":"F Wang","year":"2017","unstructured":"Wang F, Jia J, Wang J, et al. The kinetics of white blood cell and the predictive factors of leukocytosis under oral or intravenous arsenic as the first-line treatment for acute promyelocytic leukemia. Leuk Res. 2017;61:84\u20138. https:\/\/doi.org\/10.1016\/j.leukres.2017.09.006.","journal-title":"Leuk Res"},{"issue":"3","key":"5155_CR18","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3760\/cma.j.issn.0253-2727.2018.03.002","volume":"39","author":"Chinese Society of Hematology, Chinese Medical Doctor Association; Chinese Medical Association, Chinese Medical Doctor Association","year":"2018","unstructured":"Chinese Society of Hematology, Chinese Medical Doctor Association; Chinese Medical Association, Chinese Medical Doctor Association. Zhonghua Xue Ye Xue Za Zhi. 2018;39(3):179\u201383. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2018.03.002.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"5155_CR19","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1182\/blood.V94.10.3315.422k16_3315_3324","volume":"94","author":"C Niu","year":"1999","unstructured":"Niu C, Yan H, Yu T, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood. 1999;94:3315\u201324.","journal-title":"Blood"},{"issue":"7","key":"5155_CR20","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1182\/blood.2024027836","volume":"134","author":"H Zhu","year":"2019","unstructured":"Zhu H, Hu J, LoCoco F, et al. The simpler, the better: oral arsenic for acute promyelocytic leukemia. Rev Blood. 2019;134(7):597\u2013605. https:\/\/doi.org\/10.1182\/blood.2024027836.","journal-title":"Rev Blood"},{"issue":"1","key":"5155_CR21","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1080\/16078454.2020.1868782","volume":"26","author":"M Sui","year":"2021","unstructured":"Sui M, Wei H, Zhang Q, et al. Analysis of gamma-glutamyltransferase in acute promyelocytic leukemia patients undergoing arsenic trioxide treatment. Hematology. 2021;26(1):58\u201364. https:\/\/doi.org\/10.1080\/16078454.2020.1868782.","journal-title":"Hematology"},{"key":"5155_CR22","doi-asserted-by":"publisher","first-page":"107567","DOI":"10.1016\/j.leukres.2024.107567","volume":"145","author":"S Cingelova","year":"2024","unstructured":"Cingelova S, Mikuskova E, Demitrovicova L, et al. Distinctive features associated with differentiation syndrome in acute promyelocytic leukemia in patients treated by all-trans retinoic acid and arsenic trioxide. Leuk Res. 2024;145:107567. https:\/\/doi.org\/10.1016\/j.leukres.2024.107567.","journal-title":"Leuk Res"},{"issue":"3","key":"5155_CR23","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.blre.2012.01.003","volume":"26","author":"C Ganzel","year":"2012","unstructured":"Ganzel C, Becker J, Mintz PD, et al. Hyperleukocytosis, leukostasis and leukapheresis: practice management. Blood Rev. 2012;26(3):117\u201322. https:\/\/doi.org\/10.1016\/j.blre.2012.01.003.","journal-title":"Blood Rev"},{"issue":"3","key":"5155_CR24","first-page":"171","volume":"21","author":"B Jin","year":"2006","unstructured":"Jin B, Hou K, Liu Y, et al. Leukocytosis and retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. Chin Med Sci J. 2006;21(3):171\u20134.","journal-title":"Chin Med Sci J"},{"issue":"13","key":"5155_CR25","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1200\/JCO.2000.18.13.2620","volume":"18","author":"LH Camacho","year":"2000","unstructured":"Camacho LH, Soignet SL, Chanel S, et al. Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. J Clin Oncol. 2000;18(13):2620\u20135. https:\/\/doi.org\/10.1200\/JCO.2000.18.13.2620.","journal-title":"J Clin Oncol"},{"issue":"19","key":"5155_CR26","doi-asserted-by":"publisher","first-page":"4767","DOI":"10.3390\/cancers15194767","volume":"15","author":"AC Woods","year":"2023","unstructured":"Woods AC, Norsworthy KJ. Differentiation Syndrome in Acute Leukemia: APL and Beyond. Cancers (Basel). 2023;15(19):4767. https:\/\/doi.org\/10.3390\/cancers15194767. Published 2023 Sep 28.","journal-title":"Cancers (Basel)"},{"key":"5155_CR27","doi-asserted-by":"publisher","first-page":"1062524","DOI":"10.3389\/fonc.2022.1062524","volume":"12","author":"SG Iyer","year":"2023","unstructured":"Iyer SG, Elias L, Stanchina M, Watts J. The treatment of acute promyelocytic leukemia in 2023: Paradigm, advances, and future directions. Front Oncol. 2023;12:1062524. https:\/\/doi.org\/10.3389\/fonc.2022.1062524. Published 2023 Jan 18.","journal-title":"Front Oncol"},{"issue":"2","key":"5155_CR28","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s00280-018-3606-8","volume":"82","author":"C Gao","year":"2018","unstructured":"Gao C, Hu S, Guo M, Hai X, Zhou J. Clinical pharmacokinetics and safety profile of single agent arsenic trioxide by continuous slow-rate infusion in patients with newly diagnosed acute promyelocytic leukemia. Cancer Chemother Pharmacol. 2018;82(2):229\u201336. https:\/\/doi.org\/10.1007\/s00280-018-3606-8.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"5155_CR29","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1080\/17512433.2019.1586532","volume":"12","author":"M Guo","year":"2019","unstructured":"Guo M, Wang B, Liu S, et al. Time course of arsenic species in red blood cells of acute promyelocytic leukemia (APL) patients treated with single agent arsenic trioxide. Expert Rev Clin Pharmacol. 2019;12(4):371\u20138. https:\/\/doi.org\/10.1080\/17512433.2019.1586532.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"8","key":"5155_CR30","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1080\/10428194.2022.2056178","volume":"63","author":"W Macaron","year":"2022","unstructured":"Macaron W, Sargsyan Z, Short NJ. Hyperleukocytosis and leukostasis in acute and chronic leukemias. Leuk Lymphoma. 2022;63(8):1780\u201391. https:\/\/doi.org\/10.1080\/10428194.2022.2056178.","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"5155_CR31","first-page":"1085","volume":"112","author":"W Wu","year":"1999","unstructured":"Wu W, Sun G, Wu W, et al. The relationship between the levels of granulocyte colony-stimulating factor and leukocytosis induced by all-trans retinoic acid in acute promyelocytic leukemia. Chin Med J (Engl). 1999;112(12):1085\u20137.","journal-title":"Chin Med J (Engl)"},{"issue":"9","key":"5155_CR32","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1038\/sj.leu.2400756","volume":"11","author":"H Kiyoi","year":"1997","unstructured":"Kiyoi H, Naoe T, Yokota S, et al. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia. 1997;11(9):1447\u201352. https:\/\/doi.org\/10.1038\/sj.leu.2400756.","journal-title":"Leukemia"},{"issue":"1","key":"5155_CR33","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/ajh.1073","volume":"67","author":"R Foley","year":"2001","unstructured":"Foley R, Soamboonsrup P, Carter RF, et al. CD34-positive acute promyelocytic leukemia is associated with leukocytosis, microgranular\/hypogranular morphology, expression of CD2 and bcr3 isoform. Am J Hematol. 2001;67(1):34\u201341. https:\/\/doi.org\/10.1002\/ajh.1073.","journal-title":"Am J Hematol"},{"issue":"5","key":"5155_CR34","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/j.1365-2257.2005.00715.x","volume":"27","author":"K Kaito","year":"2005","unstructured":"Kaito K, Katayama T, Masuoka H, et al. CD2\u2009+\u2009acute promyelocytic leukemia is associated with leukocytosis, variant morphology and poorer prognosis. Clin Lab Haematol. 2005;27(5):307\u201311. https:\/\/doi.org\/10.1111\/j.1365-2257.2005.00715.x.","journal-title":"Clin Lab Haematol"},{"issue":"6","key":"5155_CR35","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1002\/cbin.11563","volume":"45","author":"S Yousefnia","year":"2021","unstructured":"Yousefnia S. Mechanistic effects of arsenic trioxide on acute promyelocytic leukemia and other types of leukemias. Cell Biol Int. 2021;45(6):1148\u201357. https:\/\/doi.org\/10.1002\/cbin.11563.","journal-title":"Cell Biol Int"},{"issue":"14","key":"5155_CR36","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1182\/bloodadvances.2021004789","volume":"5","author":"H Gill","year":"2021","unstructured":"Gill H, Yung Y, Chu HT, et al. Characteristics and predictors of early hospital deaths in newly diagnosed APL: a 13-year population-wide study. Blood Adv. 2021;5(14):2829\u201338. https:\/\/doi.org\/10.1182\/bloodadvances.2021004789.","journal-title":"Blood Adv"},{"key":"5155_CR37","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1080\/10428190600572673","volume":"47","author":"MJ Greenwood","year":"2006","unstructured":"Greenwood MJ, Seftel MD, Richardson C, et al. Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia. Leuk Lymphoma. 2006;47:1245\u201352. https:\/\/doi.org\/10.1080\/10428190600572673.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"5155_CR38","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/ejh.12301","volume":"93","author":"X Song","year":"2014","unstructured":"Song X, Hu X, Lu S, et al. Incorporation of arsenic trioxide in induction therapy improves survival of patients with newly diagnosed acute promyelocytic leukaemia. Eur J Haematol. 2014;93(1):54\u201362. https:\/\/doi.org\/10.1111\/ejh.12301.","journal-title":"Eur J Haematol"},{"issue":"5","key":"5155_CR39","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1111\/bjh.13189","volume":"168","author":"N Daver","year":"2015","unstructured":"Daver N, Kantarjian H, Marcucci G, et al. Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. Br J Haematol. 2015;168(5):646\u201353. https:\/\/doi.org\/10.1111\/bjh.13189.","journal-title":"Br J Haematol"},{"issue":"4","key":"5155_CR40","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1182\/blood-2008-07-168617","volume":"113","author":"P Montesinos","year":"2009","unstructured":"Montesinos P, Bergua JM, Vellenga E, et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood. 2009;113(4):775\u201383. https:\/\/doi.org\/10.1182\/blood-2008-07-168617.","journal-title":"Blood"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-05155-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05155-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05155-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T07:25:02Z","timestamp":1779693902000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-05155-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5155"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-05155-1","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"16 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki (\n                      \n                      ). The study protocol was approved by the Ethics Committee of the First Affiliated Hospital of Harbin Medical University and was exempt from informed consent owing to its observational retrospective design. Not applicable. This was a retrospective study exempt from informed consent as approved by the institutional ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"785"}}